ID   PEO1X
AC   CVCL_B3UQ
DR   cancercelllines; CVCL_B3UQ
DR   Wikidata; Q110433135
RX   CelloPub=CLPUB00667;
CC   Population: Caucasian.
CC   Doubling time: 47.84 hours (CelloPub=CLPUB00667).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Ter (c.4965C>G) (5193C>G); ClinVar=VCV000037936; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (CelloPub=CLPUB00667).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C36101; BRCA2-associated hereditary breast and ovarian cancer syndrome
DI   NCIt; C5228; Ovarian cystadenocarcinoma
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2686 ! PEO1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 05-10-23; Version: 5
//
RX   CelloPub=CLPUB00667;
RA   Lisio M.-A.;
RT   "Evaluation of platinum-sensitivity in a cell line model of high grade
RT   serous ovarian cancer and the induction of resistance from a chemo-
RT   sensitive cell line through the repopulation of cells following
RT   short-term cisplatin treatment.";
RL   Thesis PhD (2019), McGill University Montreal, Canada.
//